ConvaTec Group (LON:CTEC) Trading Down 1.3% – Here’s What Happened

Shares of ConvaTec Group PLC (LON:CTEC) fell 1.3% during trading on Tuesday . The stock traded as low as GBX 238.60 and last traded at GBX 238.60. 3,496,931 shares were traded during mid-day trading, a decline of 81% from the average session volume of 18,504,021 shares. The stock had previously closed at GBX 241.80.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CTEC. UBS Group reissued a “buy” rating and issued a GBX 375 price objective on shares of ConvaTec Group in a report on Friday, November 7th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of ConvaTec Group in a research report on Friday, November 14th. Finally, Peel Hunt reaffirmed an “add” rating and issued a GBX 270 price target on shares of ConvaTec Group in a research note on Thursday, November 13th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of GBX 318.67.

ConvaTec Group Stock Performance

The company has a debt-to-equity ratio of 85.32, a quick ratio of 0.96 and a current ratio of 2.26. The firm has a market cap of £4.65 billion, a P/E ratio of 22.45, a P/E/G ratio of 0.93 and a beta of 0.64. The company’s 50 day moving average is GBX 237.68 and its 200 day moving average is GBX 244.31.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.